Radiation-Immuno combo targets tough liver cancer clot
NCT ID NCT06823375
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding precise, high-dose radiation (SBRT) to standard immunotherapy drugs (atezolizumab plus bevacizumab) can help people with advanced liver cancer that has spread into the main portal vein. About 40 participants will receive the combination. The goal is to see if this approach improves survival and tumor control for this hard-to-treat group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab plus bevacizumab (immunotherapy drugs) and stereotactic body radiotherapy (precise high-dose radiation)
What this could lead to
If successful, this combination could improve survival and tumor control for people with advanced liver cancer and major portal vein tumor thrombosis, a group with very poor prognosis.
What could go wrong
This is a small, early-phase trial (40 participants) without a control group, so results may not be definitive. The added radiation could increase side effects, and the benefit over standard treatment is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Clinical Oncology, Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of Clinical Oncology, Tuen Mun Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact